Advertisement
Canada markets open in 4 hours 20 minutes

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7291
    +0.0010 (+0.14%)
     

  • CRUDE OIL

    79.66
    +0.66 (+0.84%)
     

  • Bitcoin CAD

    79,244.81
    +572.03 (+0.73%)
     

  • CMC Crypto 200

    1,268.96
    -1.78 (-0.14%)
     

  • GOLD FUTURES

    2,313.20
    +2.20 (+0.10%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,564.25
    +126.00 (+0.72%)
     

  • VOLATILITY

    15.02
    -0.37 (-2.41%)
     

  • FTSE

    8,151.32
    +30.08 (+0.37%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6807
    +0.0014 (+0.21%)
     

Sanofi to overhaul US operations of vaccines, cut jobs

Reuters
·1 min read
FILE PHOTO: The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon

(Reuters) - French drugmaker Sanofi said on Thursday it would restructure the U.S. com­mer­cial op­er­a­tions for its vac­cines and cut an undis­closed num­ber of jobs.

Sanofi would implement a "stream­lined strate­gic sales struc­ture" to better support its customers and patients, it said without disclosing any details on the changes to be made, the time­frame and the num­ber of em­ploy­ees to be im­pact­ed.

Endpoints News first reported the development on Thursday.

Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending.

ADVERTISEMENT

The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)